- Previous Close
23.70 - Open
22.05 - Bid --
- Ask 21.33 x --
- Day's Range
21.33 - 22.93 - 52 Week Range
15.05 - 25.40 - Volume
18,913,100 - Avg. Volume
11,173,398 - Market Cap (intraday)
9.981B - Beta (5Y Monthly) 0.53
- PE Ratio (TTM)
88.88 - EPS (TTM)
0.24 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date Aug 10, 2001
- 1y Target Est
--
Vcanbio Cell & Gene Engineering Corp., Ltd, together with its subsidiaries, primarily engages in the preparation and storage of cell detection tests in the People's Republic of China. The company provides cell test preparation and storage services for umbilical cord blood hematopoietic stem cells, umbilical cord mesenchymal stem cells, placental sub totipotent stem cells, immune cells, adipose stem cells, and dental stem cells. It also provides genetic testing services related to non-invasive prenatal genetic testing during pregnancy, genetic testing for drug safety guidance, disease genetic testing, and disease susceptibility testing for children and adults; and in vitro diagnostic raw materials, such as monoclonal antibodies and polyclonal antibody products. In addition, the company is involved in the research, development, production, and sales of biological genes, proteins, antibodies, pharmaceutical intermediates, and synthetic agents; and in vitro diagnostic reagents and medical devices. The company was founded in 1992 and is based in Tianjin, the People's Republic of China.
www.vcanbio.comRecent News: 600645.SS
View MorePerformance Overview: 600645.SS
Trailing total returns as of 4/7/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 600645.SS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 600645.SS
View MoreValuation Measures
Market Cap
11.09B
Enterprise Value
9.76B
Trailing P/E
98.75
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
6.74
Price/Book (mrq)
3.07
Enterprise Value/Revenue
6.13
Enterprise Value/EBITDA
71.71
Financial Highlights
Profitability and Income Statement
Profit Margin
6.74%
Return on Assets (ttm)
1.63%
Return on Equity (ttm)
2.71%
Revenue (ttm)
1.59B
Net Income Avi to Common (ttm)
107.45M
Diluted EPS (ttm)
0.24
Balance Sheet and Cash Flow
Total Cash (mrq)
1.44B
Total Debt/Equity (mrq)
3.37%
Levered Free Cash Flow (ttm)
156.94M